Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26/08/26	NT$80.20	+1.01%	78,095
25/08/26	NT$79.40	0.00%	60,079
24/08/26	NT$79.40	-0.75%	109,381
21/08/26	NT$80.00	+0.25%	78,789
20/08/26	NT$79.80	+0.76%	86,818

End-of-day quote Taipei Exchange

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

80.20TWD

Average target price

153.00TWD

Spread / Average Target

+90.77%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

End-of-day quote Taipei Exchange 25/08/2026			5-day change	1st Jan Change
79.40 ^TWD	0.00%		+0.25%	-1.49%

08-14	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-09	Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Brian J. Groch to Chief Commercial Officer, Effective July 1, 2026	CI

Market Cap	12.6B 395M 339M 319M 291M 549M 37.72B 552M 3.77B 1.46B 19.03B 1.48B 1.45B 63.03B	P/E 2024	-9.84x	P/E 2025	-14.1x
Enterprise Value	12.36B 388M 333M 312M 285M 538M 36.98B 541M 3.7B 1.43B 18.66B 1.46B 1.42B 61.79B	EV / Sales 2024	26x	EV / Sales 2025	28.9x
Free-Float	47.69%	Yield 2024 *	-	Yield 2025	-

08-14	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-09	Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Brian J. Groch to Chief Commercial Officer, Effective July 1, 2026	CI
06-08	Foresee Pharmaceuticals Oral ALDH2 Activator Mirivadelgat Enters Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2A Platform Trial	CI
05-27	Foresee Pharmaceuticals Completes Casppian Phase 3 Study and Confirms Topline Results for FP-001 42 Mg in Central Precocious Puberty	CI
05-14	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-06	Foresee Pharmaceuticals Announces Positive ChHMP Opinion Recommending Approval Of CAMCEVI 21 Mg 3-Month Strength In European Union	CI
02-04	Foresee Pharmaceuticals Co., Ltd. Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty	CI
12-24	Foresee Pharmaceuticals Announces Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust Lh Suppression with 6-Month Dosing Interval of Leuprolide Mesylate	CI
11-13	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/08/25	Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer	CI
12/08/25	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
31/07/25	Foresee Pharmaceuticals Co., Ltd. announced that it expects to receive TWD 400 million in funding	CI

12/08/24	Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectable Products	AQ
02/04/24	Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of CPP	AQ
31/10/23	Foresee Pharmaceuticals to Present at the American Heart Association Annual Meeting Focusing on its ALDH2 activator FP-045 in Pulmonary Hypertension Associated with Interstitial Lung Disease	AQ
02/10/23	Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	AQ
02/10/23	Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications	AQ

Foresee Pharmaceuticals Co., Ltd. Stock

Stocks

6576

TW0006576002

Biotechnology & Medical Research

Valuation : Foresee Pharmaceuticals Co., Ltd.

Chart: Foresee Pharmaceuticals Co., Ltd.

Latest news : Foresee Pharmaceuticals Co., Ltd.

Press Releases : Foresee Pharmaceuticals Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors : Foresee Pharmaceuticals Co., Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 week	+0.25%
Current month	+0.25%
1 month	-3.17%
3 months	+1.28%
6 months	-4.22%
Current year	-1.49%

1 week	78.1	80.4
1 month	76.7	81.9
Current year	75.1	88.3
1 year	71.9	93.7
3 years	57.7	107.5
5 years	57.7	141
10 years	35.1	141

Manager	Title	Age	Since
Benjamin Chien CEO	Chief Executive Officer	-	08/02/2013
Yu Hua Li CTO	Chief Tech/Sci/R&D Officer	-	09/07/2015
Max Chan DFI	Director of Finance/CFO	58	07/10/2019

Director	Title	Age	Since
Chang Jen Yan BRD	Director/Board Member	-	10/01/2013
Sheng Lee Yi BRD	Director/Board Member	-	10/01/2013
George Lee BRD	Director/Board Member	75	03/08/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORESEE PHARMACEUTICALS CO., LTD.	0.00%	+0.25%	-2.82%	+2.19%	396M
LONZA GROUP AG	-0.43%	-0.07%	+2.27%	+23.11%	50.96B
REVOLUTION MEDICINES, INC.	+2.30%	+4.26%	+480.31%	+584.28%	46.18B
BEONE MEDICINES AG	-0.52%	+0.76%	+23.93%	+84.06%	42.73B
IQVIA HOLDINGS INC.	+1.04%	+3.23%	+40.00%	+19.18%	43.04B
CELLTRION, INC.	-2.27%	-3.02%	+14.22%	+51.50%	33.48B
MEDPACE HOLDINGS, INC.	+0.29%	+1.03%	+30.72%	+136.56%	17.28B
ASCENDIS PHARMA A/S	-0.46%	-2.15%	-	-	16.43B
EUROFINS SCIENTIFIC SE	-0.25%	-0.27%	+11.45%	+28.21%	14.73B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.54%	+3.43%	+85.16%	+51.66%	14.09B
Average	+0.22%	+1.22%	+76.14%	+108.97%	27.93B
Weighted average by Cap.	+0.20%	+1.16%	+104.28%	+143.80%

	2024	2025
Net sales	419M 13.14M 11.28M 10.58M 9.67M 18.24M 1.25B 18.33M 125M 48.54M 632M 49.33M 48.26M 2.09B	431M 13.53M 11.62M 10.9M 9.96M 18.79M 1.29B 18.88M 129M 50M 651M 50.81M 49.71M 2.16B
Net income	-1.08B -33.92M -29.12M -27.33M -24.96M -47.11M -3.24B -47.33M -323M -125M -1.63B -127M -125M -5.41B	-883M -27.71M -23.79M -22.33M -20.39M -38.48M -2.64B -38.67M -264M -102M -1.33B -104M -102M -4.42B
Net Debt	-1.11B -34.74M -29.81M -27.98M -25.56M -48.23M -3.31B -48.47M -331M -128M -1.67B -130M -128M -5.54B	-248M -7.78M -6.67M -6.26M -5.72M -10.8M -742M -10.85M -74.13M -28.73M -374M -29.19M -28.56M -1.24B